Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.061 USD 7.21% Market Closed
Market Cap: 16.2m USD

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Adaptimmune Therapeutics PLC

Revenue
65.1m USD
Cost of Revenue
-44.4m USD
Gross Profit
20.7m USD
Operating Expenses
-166.2m USD
Operating Income
-145.5m USD
Other Expenses
-24.3m USD
Net Income
-169.8m USD

Margins Comparison
Adaptimmune Therapeutics PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
16.2m USD
32%
-223%
-261%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
366.9B USD
71%
31%
6%
US
US BioTec Inc
OTC:USBC
172.5B USD N/A N/A N/A
US
Amgen Inc
NASDAQ:AMGN
154.9B USD
70%
31%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
79%
38%
22%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
99.8B USD
86%
39%
32%
AU
CSL Ltd
ASX:CSL
104.8B AUD
52%
26%
19%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61B USD
86%
29%
31%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
58.2B USD
84%
-7%
-13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Adaptimmune Therapeutics PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
16.2m USD
-1 341%
-75%
-91%
-153%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
366.9B USD
113%
3%
18%
23%
US
US BioTec Inc
OTC:USBC
172.5B USD N/A N/A N/A N/A
US
Amgen Inc
NASDAQ:AMGN
154.9B USD
99%
7%
16%
14%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
33%
12%
25%
19%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
99.8B USD
23%
16%
24%
26%
AU
CSL Ltd
ASX:CSL
104.8B AUD
16%
8%
12%
10%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61B USD
15%
12%
12%
13%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
58.2B USD
-258%
-7%
-6%
-10%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less